Statum Systems Unveils Way to Replace Hospital Pagers

September 1, 2020

Statum Systems, a healthcare IT startup, today announced StatumHEALTH, a HIPAA-compliant medical communication and collaboration platform that securely connects caregivers with each other and with hospital systems and data.

“Statum Systems was founded to solve a critical problem plaguing healthcare today – inefficient and unreliable communications among care teams,” said Dr. Arman Serebrakian, a surgery resident and company co-founder.

StatumHEALTH is the only solution that allows users to receive critical messages on smartphones in locations without WiFi or cell coverage, enabling medical professionals to stop carrying pagers or other specialty communication devices.

“Caregivers are forced to constantly toggle between pagers, smartphone apps, hospital systems and telephones to access EHR and collaborate with colleagues, making it difficult to communicate competently,” added Dr. Serebrakian. “And that’s why we developed this innovation.”

StatumHEALTH’s patent-pending technology streamlines collaboration workflows and increases caseload efficiency with fast access to medical systems (like EHR) and the ability to quickly reach the right person by voice, text or video – all from a regular smartphone.

StatumHEALTH patient care sessions ensure that medical teams can conduct secure, confidential HIPAA-compliant dialogues. Built-in intelligence alerts caregivers of relevant dialogues and provides additional patient-related information upon request. StatumHEALTH collects unique communication and productivity data, enabling improved performance and quality monitoring and predictive analytics.

“Dramatically improving the way medical professionals collaborate is critical for delivering quality care,” says Fred Lizza, Statum Systems CEO. “Patients realize better health outcomes, as caregivers work with fewer communication errors and delays, and medical centers improve their financial stance. From healthcare crises to everyday operations, it’s critical for our essential caregivers to have access to the right tools.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”